Bausch Health's OraPharma Marks 25 Years of ARESTIN with Canada, Puerto Rico Expansion
Bausch Health's OraPharma marks 25 years of ARESTIN® (minocycline HCl) Microspheres, the only FDA-approved locally applied antibiotic adjunct to SRP for periodontitis. OraPharma has also expanded ARESTIN's commercial reach into Canada and Puerto Rico to improve access in regions with unmet periodontal care needs.
1. ARESTIN 25-Year Milestone
Bausch Health's OraPharma division celebrates 25 years since ARESTIN® (minocycline HCl) Microspheres was introduced as the only FDA-approved locally applied antibiotic used alongside scaling and root planing (SRP) to reduce periodontal pocket depth in adult patients with periodontitis.
2. Global Market Opportunity
Periodontal disease affects more than one billion people worldwide, creating a significant market opportunity for ARESTIN as an adjunctive non-surgical treatment option to SRP in comprehensive oral health programs.
3. Geographic Expansion
OraPharma has recently extended ARESTIN's commercial availability into Canada and Puerto Rico, aiming to address unmet needs in these regions and support dental professionals in managing chronic periodontitis.
4. Strategic Outlook
Building on two decades of clinical data, Bausch Health plans to deepen collaboration with the dental community and pursue further innovation in periodontal therapy to sustain long-term growth.